ViAqua Therapeutics Announces $8.25M Investment Led by S2G Ventures to Scale RNA-Based Solutions in Aquaculture

HAIFA, Israel, Sept. 5, 2023 /PRNewswire/ -- ViAqua Therapeutics, a biotechnology company and developer of an orally administered RNA-particle platform to promote and improve animal health in aquaculture, announced it has completed a US$8.25M round led by S2G Ventures with participation from Rabo Ventures, The Trendlines Group Ltd., Agriline Limited, Nutreco, I-Lab Angels and Circle Investments LLC.

View More